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Brain aging is associated with diminished circadian clock output and decreased expression of the core clock 
proteins, which regulate many aspects of cellular biochemistry and metabolism. The genes encoding clock 
proteins are expressed throughout the brain, though it is unknown whether these proteins modulate brain 
homeostasis. We observed that deletion of circadian clock transcriptional activators aryl hydrocarbon recep-
tor nuclear translocator–like (Bmal1) alone, or circadian locomotor output cycles kaput (Clock) in combination 
with neuronal PAS domain protein 2 (Npas2), induced severe age-dependent astrogliosis in the cortex and 
hippocampus. Mice lacking the clock gene repressors period circadian clock 1 (Per1) and period circadian 
clock 2 (Per2) had no observed astrogliosis. Bmal1 deletion caused the degeneration of synaptic terminals and 
impaired cortical functional connectivity, as well as neuronal oxidative damage and impaired expression of 
several redox defense genes. Targeted deletion of Bmal1 in neurons and glia caused similar neuropathology, 
despite the retention of intact circadian behavioral and sleep-wake rhythms. Reduction of Bmal1 expression 
promoted neuronal death in primary cultures and in mice treated with a chemical inducer of oxidative injury 
and striatal neurodegeneration. Our findings indicate that BMAL1 in a complex with CLOCK or NPAS2 regu-
lates cerebral redox homeostasis and connects impaired clock gene function to neurodegeneration.
Introduction
Circadian rhythms are controlled on a molecular level by cell-au-
tonomous core clock machinery that is present in most cells in the 
body (1, 2). Circadian output from the suprachiasmatic nucleus 
(SCN) in the hypothalamus synchronizes tissue-specific cellular 
clocks to the light-dark cycle. The core circadian clock consists of 
a set of interacting transcriptional activators and repressors. The 
activators, or “positive limb” components BMAL1 and its binding 
partners CLOCK or NPAS2 heterodimerize, bind E-box motifs, and 
regulate the transcription of a wide variety of genes (3, 4). These 
positive limb proteins drive the transcription of circadian repres-
sors, or “negative limb” components, including period (PER1-3) 
and cryptochrome (CRY1 and 2), which in turn inhibit the tran-
scriptional activity of the BMAL1:CLOCK/NPAS2 heterodimers. 
This cell-autonomous clock machinery serves to synchronize 
intracellular gene expression to external cues such as light and to 
align physiologic oscillations in cells and tissues throughout the 
body. Furthermore, each core clock gene performs unique cellular 
functions that are distinct from its role in maintaining circadian 
oscillation, implying that clock genes might control key cellular 
processes via circadian or noncircadian mechanisms (5).
In peripheral tissues, clock genes serve as critical regulators 
of cellular metabolism and redox homeostasis and have been 
implicated in the aging process (6–9). Mice with targeted dele-
tion of Bmal1 display loss of behavioral and physiologic circadian 
rhythms and develop increased systemic oxidative stress and signs 
of accelerated aging (9, 10). Conversely, aging is associated with 
diminished expression of positive-limb clock genes in mouse 
brain, and impaired circadian oscillation and oxidative injury are 
associated with brain aging and age-related neurodegenerative 
conditions in humans, suggesting a possible link between circa-
dian clock dysfunction, oxidative stress, and age-related neurode-
generation (11–15). However, it is unknown whether core clock 
genes play any role in maintaining neuronal health or if these 
genes influence neurodegeneration.
Core clock genes are expressed throughout the brain (11, 16), 
though their function and importance in brain regions other than 
the SCN are poorly understood. BMAL1 has been implicated in 
hippocampal and astrocytic function (17–20). In Drosophila, dele-
tion of the Period gene exacerbates brain pathology in neurode-
generation-prone mutants (21). In mice, Bmal1 deletion is associ-
ated with impairments in learning and memory as well as subtle 
increases in brain ROS (22), though no connection between clock 
genes and neurodegeneration has been clearly established in ver-
tebrates. Thus, we hypothesized that core circadian clock function 
might regulate redox homeostasis in the mouse brain and that 
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genetic disruption of circadian function might facilitate neuronal 
injury and neurodegeneration.
Results
Oscillation of circadian clock genes is controlled by Bmal1 in cerebral 
cortex. As circadian clock genes expressed in non-SCN brain 
regions might influence neuronal homeostasis, we examined the 
expression of selected core clock genes in cerebral cortex samples 
from young WT mice. Bmal1 and its transcriptional targets Per2 
and Dbp all demonstrated circadian oscillation with phases that 
were similar to those observed in pituitary tissue from a previous 
experiment (23), as well as to those described in rat cortex (ref. 17 
and Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI70317DS1). Expression of 
Dbp, a PAR bZIP transcription factor that is directly regulated by 
BMAL1/CLOCK-mediated transcription and serves as a marker 
of BMAL1/CLOCK transcriptional output (24), decreased by 86% 
in Bmal1 KO cortex, while expression of RevErba (Nr1d1), another 
BMAL1 target gene, decreased by 83% (Supplemental Figure 1C). 
Notably, Per2 mRNA increased by an average of 46%, perhaps due 
to loss of transcriptional repression of Per2 by RevErba, as pre-
viously described (25). Thus, core clock genes are expressed and 
oscillate with appropriate phase in cerebral cortex, and deletion of 
Bmal1 elicits transcriptional changes in non-SCN regions similar 
to those seen in peripheral tissues.
Bmal1 deletion causes age-dependent neuropathology and synaptic 
degeneration. Global Bmal1 KO mice lack circadian rhythmicity in 
gene transcription and behavior and develop a variety of pathol-
ogies reminiscent of accelerated aging (9). Thus, we examined 
brain pathology in Bmal1 KO mice at 4 to 6 months of age, before 
peripheral pathologies become severe (9). Brains from 6-month-
old Bmal1 KO mice appeared structurally normal with no devel-
opmental malformations, and cresyl violet staining demonstrated 
appropriate neural architecture with no significant thinning 
of hippocampal cell layers (Supplemental Figure 2). However, 
immunostaining for glial fibrillary acidic protein (GFAP) revealed 
striking astrocyte activation, a general marker of brain and 
neuronal injury that was most severe in cortical regions and hip-
pocampus and less evident in thalamus and brainstem (Figure 1, 
A, B, and E). Astrocytosis was age dependent, as we did not observe 
it in 2-week-old Bmal1 KO mice, but it was clearly evident by 
2.5 months of age and progressed by 6 months, as quantified 
by both Gfap mRNA levels and GFAP immunoreactivity (Fig-
ure 1, C and D). Astrocyte activation is often associated with 
increased expression of proinflammatory cytokines, including 
cyclooxygenase-2 (COX2, Ptghs2) and TNF-α (Tnfa), which exac-
erbate neurodegeneration (26, 27). We found that Ptghs2 and Tnfa 
mRNAs and COX2 protein were significantly increased in Bmal1 
KO cortex, consistent with chronic neuroinflammation (Figure 1, 
F–H). Microglial activation was generally subtle in 6-month-old 
Bmal1 KO brain, though we observed substantial activation in iso-
lated mice that lived until 8 months of age (Supplemental Figure 3). 
Fluoro-Jade C staining of Bmal1 KO cortex labeled numerous cel-
lular processes in the dentate gyrus of the hippocampus and sep-
tal nuclei, which presumably represent injured neuronal processes 
(Supplemental Figure 2E). We performed ultrastructural analysis 
of the Bmal1 KO retrosplenial cortex with transmission electron 
microscopy, which showed many activated astrocytes throughout 
the tissue (Figure 2, A–D). Neuronal cell bodies and subcellular 
organelles appeared normal, as did dendritic structures. However, 
we noted frequent abnormal axonal synaptic terminals that were 
not seen in the control tissue. These presynaptic terminals were 
swollen and devoid of normal synaptic vesicles and cytoskeletal 
architecture, suggesting degeneration (Figure 2, B and C). Interest-
ingly, the synaptic cleft itself appeared intact, as did the postsynaptic 
terminal. The axons themselves were structurally normal with intact 
myelination. Thus, Bmal1 deletion leads to widespread astrocytosis 
as well as discrete degeneration of presynaptic axonal terminals.
Functional connectivity is impaired in Bmal1 KO brain. We next 
sought to characterize the functional consequences of the neu-
ropathological changes using optical intrinsic signal functional 
connectivity imaging (fcOIS) (28). This approach visualizes altera-
tions in regional cortical blood flow in anesthetized mice and 
generates maps of resting-state functional connectivity between 
contralateral brain regions. fcOIS is highly sensitive to neuritic 
pathology in the absence of overt neuronal loss in mouse models of 
brain aging and Alzheimer disease (AD) (29). As shown in Figure 2, 
E and F, 5- to 6-month-old Bmal1 KO mice exhibited diminished 
functional connectivity throughout the cortex, most significantly 
in the retrosplenial cortex, a region that is severely affected in 
mouse models of brain aging and AD (29) and that showed severe 
astrogliosis in Bmal1 KO mice (see Figure 1E). Thus, the neuropa-
thology seen in Bmal1 KO mice coincides in space and time with 
impaired neuronal network functional connectivity.
Brain-specific deletion of Bmal1 replicates neuropathology despite intact 
behavioral rhythms and sleep-wake cycle. Mice with global deletion of 
Bmal1 have a variety of peripheral pathologies and a lack of circa-
dian oscillation in the sleep-wake cycle, which could potentially 
contribute to brain pathology (9, 10, 30). To address this, we gen-
erated NestinCre+:Bmal1flox/flox mice (referred to herein as NestinCre+; 
Bmal1f/f) in which Bmal1 is deleted in most neurons, astrocytes, 
and oligodendrocytes, with residual Bmal1 expression in microglia 
(31). These mice do not display gross peripheral pathologies. Sim-
ilar mice were previously reported to have partially intact Bmal1 
expression in the SCN, rescuing the circadian regulation of loco-
motor activity and sleep (32). Locomotor circadian rhythms were 
largely retained in our NestinCre+;Bmal1f/f mice as compared with 
mice lacking Cre, with no genotype difference in the free-run-
ning period, although there was a trend toward a slightly shorter 
free-running period, similar to that reported previously (ref. 32, Fig-
ure 3, A–C, and Supplemental Figure 4A). Using EEG, we saw that 
grossly normal sleep-wake oscillation was retained in NestinCre+; 
Bmal1f/f mice in 12-hour light/12-hour dark housing conditions 
(Supplemental Figure 4, B and C). Despite relatively normal activ-
ity and sleep rhythms, the expression and oscillation of clock genes 
were disrupted in cortex tissue from NestinCre+;Bmal1f/f. As shown 
in Figure 3D, Bmal1f/f control mice entrained to a 12-hour light/ 
12-hour dark schedule that were then placed in constant dark-
ness for 24 hours showed circadian oscillation of Bmal1, Dbp, and 
RevErba in cerebral cortex, similar to that seen in WT mice and in 
phase with rhythms observed in liver in previous experiments (see 
Supplemental Figure 1). However, expression of Dbp and RevErba, 
both BMAL1 target genes, declined by approximately 90% and 
became arrhythmic in NestinCre+;Bmal1f/f littermates (Figure 3D).
Despite intact behavioral circadian rhythms and rhythmic sleep-
wake, NestinCre+;Bmal1f/f mice showed the same severe age-depen-
dent astrogliosis we saw in global Bmal1 KO mice, as well as wide-
spread microglial activation, which was more severe than that 
observed in global Bmal1 KO mice (Figure 4, A–G). We conclude 
that the brain phenotype seen in global Bmal1 KO mice is due 
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to local loss of BMAL1 function within neurons/glia, and not to 
peripheral pathologies, changes in the sleep-wake cycle, or loss of 
peripheral circadian rhythms.
Since global Bmal1 KO mice exhibit behavioral abnormalities, 
including novelty-induced hyperactivity (22), we examined the 
performance of NestinCre;Bmal1f/f mice in a 1-hour locomotor 
behavioral test. Like Bmal1 global KOs, NestinCre+;Bmal1f/f mice 
displayed significant abnormalities in their response to a novel 
environment in 1-hour locomotor testing, as a repeated measures 
ANOVA of the total ambulation data yielded significant genotype 
by time (F statistic[5,60] = 3.06, P = 0.040), and genotype by time 
by test day (F[5,60] = 3.70, P = 0.011) interactions, while the verti-
cal rearing data yielded a significant genotype by time by test day 
(F[5,60] = 3.58, P = 0.007) interaction (Figure 4H and Supplemen-
tal Figure 5). A planned analysis of performance over the first two 
time blocks to assess novelty on day 1 yielded a significant geno-
type effect for total ambulations (F[1,12] = 6.60, P = 0.025) and 
vertical rearing (F[1,12] = 6.75, P = 0.023), with NestinCre+;Bmal1f/f 
mice showing increased total activity (block 1 P = 0.029, block 2 
P = 0.048) and number of rearings (block 1 P = 0.028) compared 
with WT controls. We found that all mice showed evidence of 
habituation on day 1 (P = 0.0004 and P < 0.00005, respectively), 
although only the control mice showed habituation on day 2 
(P = 0.022). However, for rearing frequencies, only the NestinCre+; 
Figure 1
Marked age-dependent cerebral astroglial activation in Bmal1 KO mice. GFAP staining of sections from 6-month-old WT (A) and Bmal1 KO 
(B) mice shows severe astrogliosis throughout the brain of KO mice and most severe in cortex. Scale bars: 200 μm. (C) GFAP staining of retro-
splenial cortex sections from WT and KO mice at 2 weeks of age (0.5 months), 2.5 months, and 6 months of age demonstrates age-dependent 
astrogliosis, which is present by age 2.5 months. Scale bar: 100 μm (D) Quantification of Gfap mRNA by qPCR and GFAP immunoreaction (IR; 
% area) by immunostaining of cortex samples shows age-dependent increases in astrogliosis. qPCR was normalized to 18S mRNA levels and 
is expressed as fold change compared with 2.5-month-old WT control mice. Black circles represent WT mice, and gray triangles represent KO 
mice (n = 3 mice/point). *P < 0.05 by 1-way ANOVA versus 2-week-old WT mice. (E) Region-specific astrocyte activation in Bmal1 KO brain. Ten 
mice per genotype were stained for GFAP, while 3 mice per genotype were quantified. Cing, cingulate cortex; Piri, piriform cortex; Sens, sensory 
cortex; Rs, retrosplenial cortex; Hipp, hippocampus; Str, striatum; Sept, septum; Thal, thalamus. (F) Increased COX2 protein (F and G) and Ptghs2 
mRNA (G) in 6-month-old Bmal1 KO cortex. (H) Increased Tnfa mRNA by qPCR in Bmal1 KO cortex. n = 4 mice/genotype (G and H). *P < 0.05 
versus WT by 2-way ANOVA with Bonferroni’s post test.
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Bmal1f/f mice showed habituation on day 1 (P = 0.012), while nei-
ther group showed habituation to rearing on day 2. Thus, unlike 
the previous report with global Bmal1 KO mice, it was not clear that 
NestinCre+;Bmal1f/f mice showed impaired habituation. Ultimately, 
these data are consistent with the hypothesis that NestinCre+; 
Bmal1f/f mice respond abnormally to novelty. This may represent a 
behavioral consequence of the observed neuropathology.
Bmal1 regulates redox gene expression and oxidative stress in the brain. 
Circadian clock genes have been implicated in the regulation of 
oxidative stress in several organs (9). Using mass spectrometry, we 
observed that cortical F4-neuroprostanes (F4-NPs), markers of 
neuronal membrane lipid peroxidation (33), were increased 3-fold 
in 6-month-old Bmal1 KO mice, reflective of neuronal oxidative 
damage (Figure 5A). A similar, albeit nonsignificant, trend was 
evident for F2-isoprostanes (F2-IPs) (Supplemental Figure 6A), 
general markers of lipid peroxidation in all cell types. Marked 
increases in 4-hydroxynonenal Michael adducts, markers of lipid 
peroxidation, were also observed by immunohistochemistry 
throughout the Bmal1 KO brain (Supplemental Figure 6, B and 
C). To investigate the regulation of oxidative stress by the circadian 
clock, we examined the circadian oscillation of 89 candidate genes 
(see Supplemental Table 1) known to be involved in the regulation 
Figure 2
Synaptic degeneration and impaired functional connectivity in Bmal1 KO cortex. (A–C). Electron micrographs showing presynaptic terminals 
(Sy) in 6-month-old WT (A) and Bmal1 KO (B and C) retrosplenial cortex. Note that in the Bmal1 KO cortex, the synaptic terminals are swollen 
and relatively devoid of synaptic vesicles, while the presynaptic and postsynaptic membranes, synaptic cleft, and dendritic spine (D) have normal 
morphology. Bmal1 KO mice showed both normal and abnormal terminals. (D) An activated astrocyte with a prominent Golgi complex (*) and 
islands of rough ER (**) around the nucleus (N). This cell is recognized by its abundance of intermediate filaments and cytoplasm with a lucent 
matrix. Activated astrocytes and numerous organelle-rich astrocytic processes were seen throughout the Bmal1 KO cortical tissue. Scale bars: 
500 nm. (E) Composite functional connectivity maps from all mice generated using fcOIS. Shown are the seed locations (black circle) and the map 
of connectivity with that region (red indicates a positive correlation; blue indicates a negative correlation). (F) Connectivity (correlation coefficient 
z score) between corresponding contralateral cortical regions (n = 5 mice/genotype, all 6 months of age). Cing, cingulate; Sens, sensory; Rs, 
retrosplenial; Vis, visual. *P < 0.05 by 2-way ANOVA with Bonferroni’s post test.
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of oxidative stress in several tissues using the CircaDB Circadian 
Expression Profiles database (http://bioinf.itmat.upenn.edu/
circa), which queries microarray data from several published cir-
cadian microarray experiments from non-brain tissues. Circadian 
oscillation was detected using the JTK_CYCLE nonparametric 
algorithm (34), with a P value cutoff of 0.05. We also examined the 
expression level of this same panel of genes in WT and Bmal1 KO 
pituitary tissue using previously published microarray data (ref. 35; 
GEO accession number GSE29664). From this, we identified a 
set of candidate redox genes, each of which have been previously 
implicated in neurodegeneration, including Ucp2, Sod2, Prdx6, 
Aldh2, Nfe2l2 (NRF2), and the NRF2 target genes Nqo1 and Hmox1. 
We examined the expression of these genes in WT and Bmal1 KO 
cortex at a single time point (Zeitgeber time [ZT] 6, Figure 5B and 
Supplemental Figure 7A) and in NestinCre+;Bmal1f/f brain tissue at 
ZT 0, 6, and 12 (Figure 5B and Supplemental Figure 7, A and B). 
Of these, the expression of Nqo1 and Aldh2 was significantly 
reduced in both Bmal1 KO and Nestin+;Bmal1f/f cortex as compared 
with controls at ZT 6. We thus examined the regulation of Nqo1 
and Aldh2 in more detail.
ALDH2 scavenges reactive aldehydes generated during mito-
chondrial respiration and protects neurons against oxidative 
stress–induced neurodegeneration (36, 37). In our Bmal1 KO 
cortex samples, Aldh2 mRNA levels were significantly decreased 
on average by 58% and protein by 37% at ZT 6 (Figure 5, B–D). 
Nqo1 encodes NADPH dehydrogenase (quinone 1), a critical redox 
defense enzyme that reduces toxic quinones, suppresses oxidative 
damage, and may prevent neurodegeneration (38). Nqo1 mRNA 
and protein levels were also significantly decreased in Bmal1 
KO brain, while mRNA was diminished by approximately 50% 
in NestinCre;Bmal1f/f cortex (Figure 5, B–D). We performed ChIP 
assays from WT mouse cortex to determine whether BMAL1 
directly regulates the transcription of these genes. BMAL1 binds 
to noncanonical E-box motifs in the Nqo1 promoter (Figure 5E). 
ChIP also showed that BMAL1 binds to a canonical E-box in the 
Aldh2 promoter, but does not bind a canonical E-box in the Nrf2 
Figure 3
Brain-specific deletion of Bmal1 disrupts circadian transcriptional regulation in cortex despite intact behavioral circadian rhythms. (A and B) 
Actograms showing wheel-running activity in 3- to 4-month-old Bmal1flox/flox control mice (A) and NestinCre+;Bmal1f/f mice (B). Each panel shows 
data from a representative mouse, recorded for 10 days in a 12-hour light/12-hour dark cycle, then for 30 days in constant darkness (start of con-
stant darkness denoted by arrow). (C) Free-running time for all mice analyzed in A (n = 4/genotype). There was no statistical difference between 
groups (mean = 23.56 hours for control and 23.17 hours for Nestin-Bmal1 mice; P = 0.14 by 2-tailed Student’s t test). (D) Circadian clock gene 
expression in cerebral cortex tissue from control (Bmal1f/f, Cre–) and brain-specific Bmal1 KO mice (NestinCre;Bmal1f/f, Cre+; gray triangles). 
Mice were housed in constant darkness for 24 hours, then harvested every 4 hours. mRNA levels were quantified by qPCR and were normalized 
to 18S rRNA (n = 2–4 mice/genotype/time point). RU, relative units.
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promoter. Accordingly, the NRF2 target genes heme oxygenase 1 
(Hmox1) and glutamate-cysteine ligase catalytic subunit (Gclc) 
showed nonsignificant trends toward increased expression at all 
time points in both Bmal1 KO and NestinCre+;Bmal1f/f cortex (Fig-
ure 5B and Supplemental Figure 7B), suggesting a normal NRF2-
mediated response to increased oxidative stress, and showing 
that suppressed Nqo1 and Aldh2 expression in Bmal1 KO cortex 
is not due to general inhibition of NRF2 signaling. We examined 
the circadian expression of these redox genes in cortex of Bmal1f/f 
and NestinCre+;Bmal1f/f mice and observed that Nqo1 oscillated in 
phase with other BMAL1 targets such as Dbp and RevErba (see 
Figure 3 for comparison), 
while Aldh2 and Nrf2 showed 
minimal oscillation (Figure 
5F). Nqo1 and Aldh2 mRNA 
levels decreased at all time 
points and were arrhythmic 
in NestinCre+;Bmal1f/f cortex, 
further demonstrating tran-
scriptional regulation by 
BMAL1. Thus, neuronal oxi-
dative damage is evident in 
Bmal1 KO brain, and numer-
ous redox-related transcripts 
exhibit circadian oscillation. 
Moreover, BMAL1 regulates 
the transcription of key 
redox response genes, includ-
ing Nqo1 and Aldh2.
Dual deletion of Clock and 
Npas2 phenocopies Bmal1 dele-
tion, while dual Per1 and Per2 
mutation does not. Next, we 
sought to determine whether 
the neuropathology was spe-
cific to deletion of Bmal1 or 
common to other core clock 
genes. BMAL1 can heterod-
imerize with either CLOCK 
or NPAS2 to drive gene tran-
scription. Because CLOCK 
and NPAS2 serve redundant 
roles in core clock function 
in the SCN (39) and are both 
expressed in the brain, we 
examined brains from Npas2 
KO, Clock KO, and Npas2/
Clock double-KO (DKO) 
mice for neuropathology. 
While Npas2 and Clock sin-
gle-gene KOs resembled WT 
mice, Npas2/Clock DKO mice 
recapitulated the Bmal1 KO 
phenotype, showing marked 
astroglial activation through-
out the brain, but was most 
severe in cortex (Figure 6A). 
Thus, disruption of the het-
erodimeric positive-limb tran-
scriptional complex, either via 
deletion of Bmal1 or of both of its binding partners, leads to neu-
ropathology. The negative limb of the core clock consists of several 
BMAL1 targets, including Period 1-3 (Per1-3, Figure 6B). Per1m/
Per2m double-mutant mice have disrupted circadian clock func-
tion and become immediately arrhythmic in constant darkness 
(40, 41), but have intact Bmal1 expression. In contrast to positive 
limb disruption, there was no evidence of increased astrogliosis in 
age-matched Per1m/Per2m DKO mice (Figure 6, C and D). Per1m/
Per2m cortex also showed an opposite transcriptional pattern from 
that seen in Bmal1 KO mice, with increased levels of Dbp (demon-
strating derepression of Bmal1 transcriptional activity) and Nqo1 
Figure 4
Brain-specific deletion of Bmal1 causes neuropathology and behavioral abnormalities. GFAP staining shows 
marked astrocyte activation in the retrosplenial cortex of NestinCre+:Bmal1f/f mice (C), but not in NestinCre+ 
(A) or Bmal1f/f controls (B). Hippocampal microglial activation assessed by IBA1 immunoreactivity in a rep-
resentative Cre+ control (D) and NestinCre+;Bmal1f/f mice (E). Scale bars: 200 μm. Quantification of GFAP 
(F) and IBA1 (G) immunoreactivity by percentage of area (n = 4 mice/genotype). *P < 0.05 versus control 
by 2-way ANOVA with Bonferroni’s post test. Ctx, cortex. (H) One-hour locomotor behavioral test reveals a 
significantly abnormal response to a novel environment in NestinCre+;Bmal1f/f mice (black squares) as com-
pared with Bmal1f/f controls. Data for total ambulations are shown; similar data for vertical rearings are shown 
in Supplemental Figure 5. n = 7 mice/genotype. P values from repeated-measures ANOVA are displayed for 
novelty analysis. P < 0.05 for habituation analysis for both genotypes on day 1, but only for Bmal1f/f on day 2; 
*Bmal1f/f; **NestinCre+;Bmal1f/f.
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and a trend toward increased Aldh2 (Figure 6E). Thus, deletion of 
negative limb repressors (Per1/2) enhances BMAL1-mediated tran-
scription of target genes such as Dbp and expression of Nqo1/Aldh2. 
Taken together, these findings show that transcriptional regulation 
specifically by positive-limb BMAL1:NPAS2/CLOCK heterodimers 
is required to prevent neuropathology in the brain.
Diminished Bmal1 expression exacerbates neurodegeneration in vitro 
and in vivo. In primary mouse neuron–enriched cultures, infec-
tion with a lentiviral shRNA 
(LV-shBMAL1) achieved an 
approximately 50% decrease in 
Bmal1 and an approximately 
60% decrease in Dbp mRNA 
when compared with sister 
cultures treated with an iden-
tical lentivirus expressing a 
scrambled shRNA (LV-shSCR) 
(Supplemental Figure 8). By 
day 5 after lentiviral exposure, 
LV-shBMAL1 cultures exhibited 
spontaneous neurite degener-
ation and cell death, while LV- 
shSCR–treated cells continued to 
appear healthy (Figure 7, A and 
B). Treatment with a low con-
centration of hydrogen peroxide 
(H2O2) exacerbated cell death 
even further in LV-shBMAL1 
cultures. Knockdown of Bmal1 
in Neuro2a neuroblastoma 
cells using siRNA targeted at a 
distinct sequence from the len-
tiviral shRNA did not induce 
spontaneous cell death, but did 
increase cell death caused by the 
mitochondrial toxin rotenone 
(Supplemental Figure 9, B and 
C), suggesting that the toxic 
effects of Bmal1 knockdown in 
primary neurons are not due to 
off-target effects of the shRNA. 
Conversely, siRNA-mediated 
knockdown of Bmal1 (~85% 
decrease) in primary astrocyte 
cultures had no effect on cell 
viability (Supplemental Figure 
9A), did not induce significant 
astrocyte activation (as assessed 
by Gfap mRNA upregulation), 
did not suppress Aldh2 or Nqo1 
expression, and did not induce 
inflammatory gene expression 
(Tnfa, Ptghs2, Il6), as compared 
with scrambled siRNA-treated 
cells (Figure 7C). This suggests 
that loss of Bmal1 expression in 
neurons, not astrocytes, is the 
primary driver of pathology. To 
address the hypothesis that gene 
dosage of Bmal1 might modulate 
oxidative neurodegeneration in vivo, we used the mitochondrial 
complex III inhibitor 3-nitroproprionic acid (3-NP), which induces 
oxidative injury and striatal neurodegeneration (42). We treated 
WT and Bmal1 hemizygous mice (Bmal1+/–), which show no spon-
taneous neuropathologic phenotype in the age range we examined, 
with intrastriatal stereotactic injection of 3-NP, and 3 days later 
measured striatal lesion size by cresyl violet and Fluoro-Jade C 
staining (see Supplemental Figure 10). As shown in Figure 7, D–F, 
Figure 5
Bmal1 deletion induces oxidative stress and redox defense gene dysregulation. (A) Increased F4-NP levels 
as quantified by liquid chromatography tandem mass spectrometry (LC-MS/MS) in 6-month-old Bmal1 KO 
cortex, indicative of neuronal membrane lipid peroxidation (n = 5 mice/genotype). (B) Quantification of Dbp 
and redox gene expression in Bmal1 KO and NestinCre+;Bmal1f/f cortex versus controls at ZT 6 (n = 5–6 
mice/genotype). Bmal1 KO values were normalized and compared with WT cortex, while NestinCre+; 
Bmal1f/f values were normalized and compared with NestinCre+ controls. (C) Representative Western blots 
showing decreased NQO1 (upper blots) and ALDH2 (lower blots) protein in Bmal1 KO brain at ZT 6. ERK is 
shown as a loading control. (D) Quantification of ALDH2 and NQO1 protein (n = 5 mice/genotype). Shown 
is the mean + SEM for all graphs. *P < 0.05 versus control by Student’s t test (A) or 2-way ANOVA with 
Bonferroni’s post test (B and D). (E) ChIP assay in WT mice at ZT 6 demonstrating that BMAL1 does not 
bind to a canonical E-box in the Nrf2 promoter, but does bind a noncanonical E-box in the Nqo1 promoter 
and a canonical E-box in the Aldh2 promoter. Total lysate (input, positive control) and immunoprecipitates 
prepared using nonspecific IgG (negative control) are shown. (F) BMAL1 regulates cortical expression of 
Nqo1 and Aldh2, but not Nrf2. Frontal cortex samples were collected every 4 hours from Bmal1f/f control 
mice (black circles) or NestinCre+;Bmal1f/f mice (gray triangles) as in Figure 3D, and redox genes were 
quantified by qPCR (n = 2–3 mice/time point/genotype).
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Bmal1+/– mice had significantly larger lesions than WT mice, sup-
porting the notion that Bmal1 expression levels play a critical role 
in neuronal redox homeostasis and neurodegeneration.
Discussion
It is now evident that core clock genes regulate critical aspects of 
cellular biology in many organs and that disruption of normal 
core clock function may precipitate disease pathology. Indeed, 
impaired clock gene expression in mice can cause a variety of 
pathologies, including diabetes, vascular disease, obesity, and 
accelerated aging (6, 8, 9, 43). Despite these findings, relatively lit-
tle is known about the role of clock genes in other brain regions. 
Our results show that disruption of the positive limb of the circa-
dian clock in the brain, either via deletion of Bmal1 (either glob-
ally on in a brain-specific manner) or Npas2 and Clock, induces 
oxidative stress, widespread astrocyte activation, axonal terminal 
degeneration, and disrupted resting-state functional connectiv-
ity. This neuropathology is not due to a disruption in peripheral 
physiology, sleep disruption, or systemic circadian mechanisms 
and is not recapitulated by mutation of the negative-limb genes 
Per1 and Per2. The degree of astrogliosis and oxidative stress do 
not perfectly correlate, as thalamus shows minimal astrogliosis 
but significant increases in 4-HNE, suggesting that the region-
ality of brain pathology in Bmal1 KO mice is driven both by the 
degree of oxidative damage and the inherent susceptibility of a 
given region. The expression levels of Bmal1 appear to be critical, as 
Bmal1+/– mice, though not exhibiting overt pathology or circadian 
phenotype, are more sensitive than WT mice to oxidative neurode-
generation caused by the mitochondrial inhibitor 3-NP, while even 
partial knockdown of Bmal1 in primary neurons induces sponta-
neous neurodegeneration. These data reveal a critical role for the 
circadian clock positive-limb transcriptional complex (BMAL1: 
CLOCK/NPAS2) in neuronal redox homeostasis and protection 
from neurodegeneration.
BMAL1:NPAS2/CLOCK heterodimers regulate the transcription 
of many circadian and noncircadian genes, and both sets of tran-
scripts are likely relevant to neuronal function (5). In our studies, 
the neuropathology in Bmal1 KO and Clock/Npas2 DKO mice does 
not appear to be due to loss of systemic circadian rhythms or sleep-
wake disturbance, since (a) NestinCre+;Bmal1f/f mice develop neu-
ropathology despite normal behavioral rhythms and sleep-wake 
oscillation; (b) Per1m/Per2m mice, which have impaired circadian 
rhythms, do not develop pathology; and (c) Bmal1+/– mice, which 
exhibit normal circadian oscillation, have enhanced sensitivity to 
3-NP–induced neurodegeneration. It thus appears that the levels 
of Bmal1 and/or Clock and Npas2 are the important factors, rather 
than the circadian oscillation of transcripts. However, the levels 
and activity of Bmal1, Npas2, and Clock are intimately tied to circa-
dian oscillation, and conditions that disrupt oscillation can sup-
press Bmal1 expression or transcriptional activity. These include 
cellular senescence, sleep deprivation, and pulsed-light exposure 
(44–46). Therefore, these circadian “stressors” may predispose 
individuals to age-related neurodegeneration by suppressing posi-
tive-limb clock gene expression and activity. Circadian dysfunction 
Figure 6
Genetic disruption specifically of the positive limb of the circadian clock causes neuropathology. (A) GFAP staining of retrosplenial cortex from 
4-month-old Npas2 KO, Clock KO, Npas2/Clock DKO, and Bmal1 KO mice shows that complete disruption of the positive limb of the core clock 
(depicted in B) is required to elicit neuropathology. (C) Absence of astrogliosis in retrosplenial cortex from 4-month-old Per1m/Per2m mice, which 
lack negative limb clock function and have dysfunctional circadian oscillation. (D) Quantification of GFAP immunoreactivity in Per1m/Per2m mice 
(% area). NestinCre+;Bmal1f/f cortex is shown for comparison. (E) qPCR data from 4-month-old Per1m/Per2m cortex show a transcriptional profile 
opposite that of Bmal1 KO brain (see Figure 1). (D and E) n = 4 mice/genotype. *P < 0.05 versus control by 2-way ANOVA with Bonferroni’s post 
test. Scale bars: 50 μm (A and C).
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is observed in several neurodegenerative diseases, including AD 
and Parkinson disease (12, 13, 47), suggesting that disease-related 
loss of clock gene function might impact pathogenesis and disease 
progression. Accordingly, epidemiologic data show that dimin-
ished circadian function in humans imparts an increased risk of 
developing future dementia (48). Our findings suggest that fur-
ther study of the regulation of circadian clock genes in non-SCN 
brain regions in aging and neurodegenerative diseases is warranted 
and that therapies targeted at bolstering positive-limb clock gene 
expression in the brain might have neuroprotective effects.
Aging is a major risk factor for neurodegenerative diseases, and 
the core clock is intimately intertwined with the aging process, as 
aging impairs the expression of Bmal1 and Clock (11), while disrup-
tion of Bmal1 recapitulates many aspects of age-related pathology 
(9). In vascular smooth muscle cells, senescence is associated with 
a marked decline in Bmal1 expression (44), while the expression 
of Bmal1 and Clock in cerebral cortex is substantially diminished 
in aged mice (11). Our results predict that aging-related declines 
in Bmal1 expression in the brain could impair redox defense gene 
expression, exacerbate oxidative stress, and facilitate neurodegen-
eration. Indeed, aged brain shares many characteristics with Bmal1 
KO brain, including increased oxidative damage, diminished redox 
defense gene expression, increased Ptghs2 expression, and impaired 
retrosplenial functional connectivity. Thus, declining positive-limb 
core clock activity in non-SCN brain may be part of a feed-forward 
cycle with aging, which may exacerbate specific age-related patho-
genic events that contribute to neurodegeneration (49–52).
Our findings, as well as previous studies, suggest that the core 
clock plays an important role in redox homeostasis. Bmal1 KO 
mice exhibit increased ROS levels in spleen, kidney, and brain, 
and treatment with the glutathione precursor N-acetyl cysteine 
extends lifespan in these mice (9, 22, 53). The cellular redox state 
shows circadian oscillation, which is dependent on Bmal1 expres-
sion both in cultured fibroblasts and the mouse SCN (54, 55). 
Furthermore, the acetylation of multiple critical mitochondrial 
proteins shows circadian oscillation, suggesting clock-mediated 
control of the mitochondrial redox state (56). Conversely, clock 
function is modulated by the redox state of the cell (7, 57, 58). 
In the brain, our observation of impaired expression of Aldh2 and 
Nqo1, despite ongoing oxidative stress, suggests that the core clock 
is required for appropriate protective responses to oxidant injury, 
illustrating a new aspect of this relationship between the clock 
Figure 7
Diminished Bmal1 expression enhances neurodegeneration. (A and B). Bmal1 knockdown in primary neuronal cultures induces neuronal 
death. (A) Representative phase-contrast photomicrographs from DIV 7 mouse cortical neuron–enriched cultures 5 days after treatment with 
LV expressing scrambled shRNA (LV-scr) or BMAL1 shRNA (LV-shBMAL1) and after 24 hours of treatment with vehicle (Con) or H2O2. Original 
magnification, ×10. (B) Quantification of cell viability as assessed by MTT assay. Data are representative of three independent experiments. (C) 
siRNA-mediated knockdown of Bmal1 in primary astrocyte cultures does not induce astrocyte activation or suppress Nqo1 or Aldh2 transcription. 
mRNA levels quantified by qPCR and normalized to 18S rRNA. Data are expressed as fold change from sister cultures transfected with scrambled 
siRNA. The mean ± SEM of four separate experiments is shown. *P < 0.05 by 1-way ANOVA with Bonferroni’s post test. (D and E) Representative 
photomicrographs showing area of striatal neurodegeneration (dotted line) in WT (D) and Bmal1 hemizygous (E) mice 3 days after intrastriatal 
injection of 3-NP. Scale bar: 250 μm. (F) Quantification of 3-NP striatal lesion volume as assessed by cresyl violet staining. *P < 0.05 by 2-way 
ANOVA with a Bonferroni’s post test, as compared with control condition. het, heterodimer.
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Western blotting. Tissue samples were homogenized by sonication on ice 
in radioimmunoprecipitation (RIPA) buffer (Pierce, Thermo Scientific) 
containing cOmplete protease inhibitors and PhosSTOP phosphatase 
inhibitors (Roche). PAGE and Western blotting were performed using 
Invitrogen Novex gels and reagents and an iBlot transfer device per the 
manufacturer’s instructions. Bands were visualized using Lumigen 
TMA-6 chemiluminescence reagents on a Syngene GBOX imaging sys-
tem. Band intensity was quantified using ImageJ software (NIH) and was 
normalized to the ERK loading control.
qPCR. For RNA isolation, brain tissue was homogenized by trituration 
through a 23-gauge needle in TRIzol (Invitrogen). Chloroform (1:5) was 
added, samples were agitated then centrifuged at 13,000 g for 15 minutes 
at 4°C, and the chloroform layer was removed, diluted 1:1 in 70% ethanol, 
then purified using RNeasy columns and reagents (QIAGEN). RNA concen-
tration was measured using a NanoDrop spectrophotometer, and reverse 
transcription was performed using a high-capacity RNA-cDNA kit (Applied 
Biosystems [ABI]) with 1 μg RNA per 20 μl reaction. Real-time qPCR was 
performed using ABI TaqMan primers and reagents on an ABI Prizm 7500 
thermocycler according to the manufacturer’s instructions. All mRNA mea-
surements were normalized to 18S rRNA or β-actin mRNA levels.
Primary neuronal and astrocyte cultures. Primary cultures were prepared 
from E17 C57/Bl6 WT cerebral cortices, which were dissected and incu-
bated in 5 ml HBSS containing 3 mg bovine pancreatic trypsin (Sigma- 
Aldrich) at 37°C for 15 minutes. Cortices were then gently triturated in 
warm HBSS plus 10% FBS, diluted in warmed MEM with 10% FBS to a 
concentration of 275,000 cells/ml, and then added to 24- or 96-well plates 
precoated with poly-D-lysine (50 μg/ml; Sigma-Aldrich) and laminin 
(25 μg/ml; Invitrogen). After 24 hours, 60% of the media was replaced with 
neurobasal media plus 1X B27 supplement and 5 mM L-glutamine. Lenti-
virus was added to neurons on days in vitro (DIV) 2 at a concentration of 
1 × 106 trophic units (TU) per milliliter for all viruses (2.5 TU/cell). On 
DIV 4, lentivirus-containing media were removed and replaced with neuro-
basal plus B27 and glutamine. On DIV 6 (4 days after lentiviral exposure), 
the media were changed to neurobasal plus B27 without antioxidants, with 
or without 10 μM hydrogen peroxide. Twenty-four hours later, the cells 
were harvested for RNA extraction, or cell viability was determined by MTT 
assay. For astrocyte cultures, P1 mice were dissected as described above. 
Cells were diluted in DMEM with F-12 supplement (Invitrogen) and 15% 
FBS and 10 ng/ml epidermal growth factor (Sigma-Aldrich).
Immunohistochemistry. Immunostaining was performed as previously 
described (29). Briefly, mice were anesthetized via i.p. pentobarbital, 
then perfused for 3 minutes with ice-cold Dulbecco’s modified PBS 
(DPBS) containing 3 g/l heparin. One hemisphere was fixed in 4% para-
formaldehyde for 24 hours (4°C), then cryoprotected with 30% sucrose 
in PBS (4°C) for 48 hours, and 50-micron serial coronal sections were 
cut on a freezing sliding microtome. Sections were incubated in 0.3% 
hydrogen peroxide for 10 minutes, blocked for 30 minutes in TBS con-
taining 3% serum and 0.25% Triton X-100, then incubated overnight in 
TBS plus 0.25% Triton X-100 (Sigma-Aldrich) with primary antibody and 
1% serum at 4°C. Sections were incubated for 1 hour with biotinylated 
secondary antibody, then washed and incubated with 1:400 dilution of 
streptavidin-conjugated HRP (VECTASTAIN ABC Elite; Vector Labora-
tories), then with diaminobenzidine substrate with hydrogen peroxide 
and nickel chloride.
Quantification of immunoreactivity. Images from a given brain region from 
three sections per mouse that were 150 microns apart were converted to 
grayscale, thresholded such that all GFAP immunoreactivity was included, 
then the percentage of area was calculated using ImageJ software. Sections 
from all mice included in a given analysis were stained in a single batch, 
and threshold values were held constant for all mice in that batch. The 
and ROS. Aldh2 and Nqo1 are directly regulated by BMAL1, and 
their expression is diminished when Bmal1 is deleted. However, the 
expression of both genes increases in parallel with Dbp (a marker 
of positive-limb transcriptional activity) in Per1m/Per2m DKO 
brain, suggesting that alleviation of Per1/2-mediated repression of 
BMAL1 transcriptional activity enhances Aldh2 and Nqo1 expres-
sion. Both NQO1 and ALDH2 are critical mediators of the cellular 
antioxidant response and are closely linked to neurodegeneration. 
ALDH2 scavenges reactive electrophiles within mitochondria, and 
deletion of Aldh2 in mice causes oxidative damage and neuronal 
death, while impaired ALDH2 activity has been implicated as 
a cause of dopaminergic neurodegeneration in Parkinson dis-
ease (36, 37). NQO1 catalyzes the reduction of reactive quinones 
and oxidized proteins, prevents ROS-mediated cytotoxicity, and 
is upregulated in vulnerable brain regions in AD (38, 59). Thus, 
impaired Aldh2 and Nqo1 expression may contribute to neuronal 
pathology in Bmal1 KO brain.
In summary, our findings draw a novel link between the core cir-
cadian clock, brain oxidative stress, and neurodegeneration. This 
relationship has many potential implications for age-related neu-
rodegenerative diseases and suggests that further study of the reg-
ulation and function of core clock genes in non-SCN brain regions 
in health and disease is warranted.
Methods
Reagents. The following antibodies were used: ALDH2 and NQO1 mono-
clonals (Epitomics); BMAL1 polyclonal (Bethyl Laboratories, Inc.); COX2 
polyclonal (Cayman Chemical); ERK (Cell Signaling Technology); GFAP 
(Dako); IBA1 (Wako); and 4-HNE Michael Adduct (EMD Millipore). 
Cell culture media and reagents (neurobasal media, B27 supplement) 
and TaqMan quantitative PCR (qPCR) primer sets were obtained from 
Invitrogen. 3-Nitropropionic acid was purchased from Sigma-Aldrich.
Mice. Bmal1+/–, NestinCre+, and Bmal1f/f mice were obtained from The Jack-
son Laboratory and were bred at Washington University. A second strain of 
NestinCre+;Bmal1f/f mice was bred at the University of Pennsylvania and was 
used in some experiments. A second strain of Bmal1+/– mice was originally 
obtained from C. Bradfield (University of Wisconsin, Madison, Wiscon-
sin, USA) and bred at the University of Pennsylvania. Npas2 KO (originally 
provided by S. McKnight, UT Southwestern Medical School, Dallas, Texas, 
USA), Clock KO, and Npas2/Clock DKO mice were bred and housed at the 
University of Massachusetts Medical School. Per1ldc/Per2ldc (referred to 
herein as Per1m/Per2m) were originally provided by S. Reppert (University of 
Massachusetts, Worcester, Massachusetts, USA) and were bred at Washing-
ton University. All mice were maintained on a C57Bl6 background. Mice 
were housed under 12-hour light/12-hour dark conditions.
Optical imaging of functional connectivity. OIS imaging of resting-state 
functional connectivity in mice was performed as previously described 
(28, 29). Briefly, mice were anesthetized with an i.p. ketamine/xylazine 
mixture (86.9 mg/kg ketamine, 13.4 mg/kg xylazine) and allowed 
30 minutes for anesthetic transition. Once induced, each animal was 
placed on a heating pad maintained at 37°C (mTCII; Cell MicroControls) 
and its head secured in a stereotactic frame. Next, the scalp was reflected, 
exposing approximately 1 cm2 of the skull. Sequential illumination of the 
skull surface was provided at four wavelengths by a ring of light-emitting 
diodes placed approximately 10 cm above the mouse’s head. Images were 
captured using a cooled, frame-transfer EMCCD camera (iXon 897; Andor 
Technology), which was time synchronized and controlled via computer 
using custom-written software (MATLAB; MathWorks). Images were 
acquired at a frame rate of 120 Hz, and 7–9 five-minute imaging sessions 
were performed per mouse.
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mean percentage of the area for each region from each mouse was com-
piled for statistical analysis.
LV preparation. shRNA sequences targeting Bmal1 (Arntl, clone 
NM_007489.1-2418s1c1, CCATTGATACAAGTCAATCTA) or a scrambled 
sequence were cloned into a lentiviral vector containing a U6 promoter 
(ubiquitous expression) upstream of the shRNA as well as a phosphoglyc-
erate kinase (Pgk) promoter driving a GFP tag.
3-NP treatment. Sterile 3-NP (100 nmol/μl) in PBS (pH 7.4) was injected 
with a 30-gauge Hamilton syringe needle at the following coordinates 
relative to the bregma: +0.98 mm anterior, +1.5 mm lateral, and depth of 
2.6 mm. The needle was left in place for 5 minutes, then 0.5 μl (total of 
50 nmol) of 3-NP was injected over a 5-minute period. Three days later, the 
mice were perfused as described above.
siRNA experiments. siRNAs (scrambled or Bmal1 targeted) were obtained 
from Thermo Scientific (Dharmacon SMARTpool siRNAs, which consists 
of a pool of 5 siRNA targeting Bmal1). Neuro2a neuroblastoma cells (ATCC) 
were cultured in DMEM plus 10% FBS and were plated at a density of 3 × 105 
cells/ml (0.5 ml per well in a 24-well plate). One microliter of 20 μM siRNA 
was added to each well. Neuro2a cells were transfected with Lipofectamine 
2000 reagent, while astrocytes were transfected with RNAiMax reagent (both 
from Invitrogen), according to the manufacturer’s instructions.
Additional methods, including behavioral testing, electron micros-
copy, ChIP, mass spectrometry, and Fluoro-Jade staining, are available in 
the Supplemental Methods.
Statistics. A 2-tailed Student’s t test was used when a single variable was 
compared between two genotypes, and 2-way ANOVA with Bonferroni’s 
post test was used when multiple variables were compared between geno-
types. The cutoff for significance was P < 0.05. In all figures, the graphs 
depict the mean ± SEM.
Study approval. All animal studies were performed in accordance with 
protocols approved by the Animal Studies Committees of Washington 
University and the University of Pennsylvania.
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